This white paper looks at development work being undertaken in Cambridge to create a new state of the art omics analysis hardware and software platform – using the open source software framework OpenCB and new, high performance hardware from Dell and Intel.
Within the life science industry, a widening omics / Moore’s law gap is occurring. This is produced by the much faster rate of improvement – and consequent price drop – seen in omics technologies, as compared to compute and data technologies.
This is in turn is leading to an omics analysis bottle neck that is not sustainable, since most of the current hardware and software platforms are not designed to work with current large data volumes.
This paper looks at development work being undertaken at Cambridge to create a new state of the art omics analysis hardware and software platform, utilising the open source software framework OpenCB and new high performance hardware from Dell and Intel.
With this new OpenCB omics analysis platform, current day high volume omics analysis problems become tractable.
Such advances in analytics platforms are vital in order to translate advances in population scale omics and medical informatics projects into personalised medicine technologies deployed in the clinic – and to finally realise the step change in human health that these technologies have the potential to enable.
White paper ®Dell
Dell Corporation Limited is authorised and regulated in the UK by the Financial Conduct Authority for consumer credit brokerage. Registered in England and Wales. Company Registration Number: 2081369
Our website: www.dell.co.uk